45 Stocks Moving In Monday’s Mid-Day Session
Gainers
Aterian, Inc. (NASDAQ: ATER) jumped 54.1% to $18.18. Investor presentation released on Friday is now circulating on news outlets.
HC Wainwright & Co. Maintains Buy on aTyr Pharma, Raises Price Target to $18
HC Wainwright & Co. analyst Joseph Pantginis maintains aTyr Pharma (NASDAQ:LIFE) with a Buy and raises the price target from $13 to $18.
ATyr Pharma’s Lead Candidate Shows Promise In Inflammatory Lung Disease
ATyr Pharma Inc (NASDAQ:LIFE) has announced positive results from its Phase 1b/2a trial evaluating its lead therapeutic candidate, ATYR1923, in pulmonary…
aTyr Pharma: Q2 Earnings Insights
Shares of aTyr Pharma (NASDAQ:LIFE) fell in after-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share increased 7.25% over the past year to ($0.64), which missed the estimate of ($0.51).
aTyr Pharma Q2 EPS $(0.64) Misses $(0.51) Estimate
aTyr Pharma (NASDAQ:LIFE) reported quarterly losses of $(0.64) per share which missed the analyst consensus estimate of $(0.51) by 25.49 percent. This is a 7.25 percent increase over losses of $(0.69) per share from the
aTyr Pharma Reports Expansion Of Its Research Collab With Ohio State University
aTyr Pharma, Inc. (NASDAQ:LIFE), a clinical stage biotherapeutics company, today announced that the company has expanded its research collaboration with The Ohio State University (OSU) to deepen the understanding of the
The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck’s Keytruda On Track For More Label Expansions, Eliem Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 9)
Earnings Scheduled For August 10, 2021
Companies Reporting Before The Bell
• Nautilus Biotechnology (NASDAQ:NAUT) is expected to report earnings for its second quarter.
aTyr Pharma Announces Two Abstracts for ATYR1923 Accepted for Presentation at the European Respiratory Society International Congress
aTyr Pharma, Inc. (NASDAQ:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that two abstracts for the company's